U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29O4.K
Molecular Weight 396.5616
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANRENOATE POTASSIUM

SMILES

[K+].[H][C@@]12CC[C@@](O)(CCC([O-])=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=CC4=CC(=O)CC[C@]34C

InChI

InChIKey=JTZQCHFUGHIPDF-RYVBEKKQSA-M
InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/25389106

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is not licensed in the UK, but may sometimes be prescribed off-licence to treat oedema. It is given intravenously. Potassium canrenoate is a mineralocorticoid receptor (MR) antagonist. The blockade with MR antagonist have beneficial effects in patients with heart failure and myocardial infarction, often attributed to blocking aldosterone action in the myocardium.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Phase III
656
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Ouabain-inhibiting activity of aldosterone antagonists.
1995 Jan
Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry.
2001 Jun
Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy.
2001 Mar
[The influence of various adjuvant drugs used in intensive care on monocyte chemotaxis].
2002 Aug
Are some progestins genotoxic liver carcinogens?
2002 Dec
The renin-angiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study.
2003 Oct 29
Effects of pH and the presence of micelles on the resolution of diuretics by reversed-phase liquid chromatography.
2004 Jan 2
Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.
2005 Mar
Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization.
2005 Mar
Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism.
2005 May
Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade.
2005 Oct
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.
2005 Sep
A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
2006
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases.
2006 Mar
Cirrhotic cardiomyopathy.
2007 Mar 27
Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate.
2008 Apr
Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
2008 Jan
Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor.
2008 Jun
Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism.
2009 Apr 7
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows.
2009 Sep 1
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
2010
Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: an assessment.
2010 Apr
Amiloride reduces portal hypertension in rat liver cirrhosis.
2010 Jun
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans.
2010 Jun
Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial.
2010 Oct
Patents

Patents

US2011257140
3
US2014322323
3

Sample Use Guides

In Vivo Use Guide
400 mg of Potassium-Canrenoate
Route of Administration: Intravenous
In Vitro Use Guide
potassium canrenoate, in a concentration-dependent manner (3-30 uM), inhibited the increase in basal tone induced by receptorial (ouabain), most likely acting as antagonist for ouabain binding site on Na(+)-K+ATPase pump
Name Type Language
CANRENOATE POTASSIUM
USAN  
USAN  
Official Name English
CANRENONE FREE ACID POTASSIUM SALT [MI]
Common Name English
NSC-757789
Code English
CANRENOATE POTASSIUM [USAN]
Common Name English
KANRENOL
Brand Name English
POTASSIUM CANRENOATE [MART.]
Common Name English
POTASSIUM CANRENOATE [JAN]
Common Name English
POTASSIUM CANRENOATE
INN   MART.   WHO-DD  
INN  
Official Name English
SOLDACTONE
Brand Name English
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO-, MONOPOTASSIUM SALT (17.ALPHA.)-
Common Name English
CANRENONE FREE ACID POTASSIUM SALT
MI  
Common Name English
potassium canrenoate [INN]
Common Name English
Potassium 17-hydroxy-3-oxo-17α-pregna-4,6-diene-21-carboxylate
Common Name English
Potassium canrenoate [WHO-DD]
Common Name English
SC-14266
Code English
Classification Tree Code System Code
NCI_THESAURUS C547
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
WHO-VATC QC03DA02
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
WHO-ATC C03DA02
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
Code System Code Type Description
RXCUI
1981
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1616951
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
DRUG BANK
DB09015
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
NCI_THESAURUS
C81161
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
FDA UNII
M671F9NLEA
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
INN
2448
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
218-554-9
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
NSC
757789
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
MESH
D002191
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID2045602
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
PUBCHEM
23671691
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
WIKIPEDIA
POTASSIUM CANRENOATE
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
DRUG CENTRAL
477
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
SMS_ID
100000091863
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
CAS
2181-04-6
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
MERCK INDEX
m3023
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY Merck Index
EVMPD
SUB09983MIG
Created by admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of CANRENOIC ACID
SUBSTANCE RECORD
Structure of CANRENOATE POTASSIUM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966